INTEGRA LIFESCIENCES HOLDING (IART) Fundamental Analysis & Valuation

NASDAQ:IART • US4579852082

9.73 USD
-0.16 (-1.62%)
At close: Mar 6, 2026
9.73 USD
0 (0%)
After Hours: 3/6/2026, 8:24:59 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This IART fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Taking everything into account, IART scores 3 out of 10 in our fundamental rating. IART was compared to 184 industry peers in the Health Care Equipment & Supplies industry. IART may be in some trouble as it scores bad on both profitability and health. IART is valued quite cheap, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

3

1. IART Profitability Analysis

1.1 Basic Checks

  • IART had positive earnings in the past year.
  • IART had a positive operating cash flow in the past year.
  • In multiple years IART reported negative net income over the last 5 years.
  • Each year in the past 5 years IART had a positive operating cash flow.
IART Yearly Net Income VS EBIT VS OCF VS FCFIART Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M -400M

1.2 Ratios

  • The Return On Assets of IART (-14.34%) is comparable to the rest of the industry.
  • IART's Return On Equity of -49.50% is in line compared to the rest of the industry. IART outperforms 49.46% of its industry peers.
  • IART has a Return On Invested Capital of 4.34%. This is in the better half of the industry: IART outperforms 74.46% of its industry peers.
  • IART had an Average Return On Invested Capital over the past 3 years of 5.05%. This is below the industry average of 8.92%.
Industry RankSector Rank
ROA -14.34%
ROE -49.5%
ROIC 4.34%
ROA(3y)-4.24%
ROA(5y)-0.72%
ROE(3y)-15.23%
ROE(5y)-5.13%
ROIC(3y)5.05%
ROIC(5y)5.6%
IART Yearly ROA, ROE, ROICIART Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 -20 -30 -40

1.3 Margins

  • IART has a better Operating Margin (10.58%) than 78.80% of its industry peers.
  • IART's Operating Margin has declined in the last couple of years.
  • IART's Gross Margin of 56.62% is in line compared to the rest of the industry. IART outperforms 57.07% of its industry peers.
  • IART's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 10.58%
PM (TTM) N/A
GM 56.62%
OM growth 3Y-17.47%
OM growth 5Y-7.89%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.52%
GM growth 5Y-2.59%
IART Yearly Profit, Operating, Gross MarginsIART Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. IART Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), IART is destroying value.
  • The number of shares outstanding for IART has been increased compared to 1 year ago.
  • IART has less shares outstanding than it did 5 years ago.
  • The debt/assets ratio for IART is higher compared to a year ago.
IART Yearly Shares OutstandingIART Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
IART Yearly Total Debt VS Total AssetsIART Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

2.2 Solvency

  • Based on the Altman-Z score of 1.19, we must say that IART is in the distress zone and has some risk of bankruptcy.
  • IART has a Altman-Z score of 1.19. This is comparable to the rest of the industry: IART outperforms 52.72% of its industry peers.
  • A Debt/Equity ratio of 1.66 is on the high side and indicates that IART has dependencies on debt financing.
  • IART has a worse Debt to Equity ratio (1.66) than 80.43% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.66
Debt/FCF N/A
Altman-Z 1.19
ROIC/WACC0.61
WACC7.1%
IART Yearly LT Debt VS Equity VS FCFIART Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

2.3 Liquidity

  • A Current Ratio of 2.54 indicates that IART has no problem at all paying its short term obligations.
  • IART has a Current ratio (2.54) which is in line with its industry peers.
  • A Quick Ratio of 1.46 indicates that IART should not have too much problems paying its short term obligations.
  • The Quick ratio of IART (1.46) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.54
Quick Ratio 1.46
IART Yearly Current Assets VS Current LiabilitesIART Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. IART Growth Analysis

3.1 Past

  • The earnings per share for IART have decreased strongly by -12.89% in the last year.
  • Measured over the past years, IART shows a decrease in Earnings Per Share. The EPS has been decreasing by -1.86% on average per year.
  • The Revenue has been growing slightly by 1.53% in the past year.
  • IART shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.57% yearly.
EPS 1Y (TTM)-12.89%
EPS 3Y-12.69%
EPS 5Y-1.86%
EPS Q2Q%-14.43%
Revenue 1Y (TTM)1.53%
Revenue growth 3Y1.63%
Revenue growth 5Y3.57%
Sales Q2Q%-1.74%

3.2 Future

  • IART is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.77% yearly.
  • IART is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.86% yearly.
EPS Next Y7.01%
EPS Next 2Y7.98%
EPS Next 3Y7.77%
EPS Next 5YN/A
Revenue Next Year2.71%
Revenue Next 2Y3.05%
Revenue Next 3Y2.86%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
IART Yearly Revenue VS EstimatesIART Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 500M 1B 1.5B
IART Yearly EPS VS EstimatesIART Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

7

4. IART Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 4.36, the valuation of IART can be described as very cheap.
  • Based on the Price/Earnings ratio, IART is valued cheaper than 99.46% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.29. IART is valued rather cheaply when compared to this.
  • A Price/Forward Earnings ratio of 4.08 indicates a rather cheap valuation of IART.
  • Based on the Price/Forward Earnings ratio, IART is valued cheaply inside the industry as 99.46% of the companies are valued more expensively.
  • IART's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.57.
Industry RankSector Rank
PE 4.36
Fwd PE 4.08
IART Price Earnings VS Forward Price EarningsIART Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, IART is valued cheaper than 97.28% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 7.19
IART Per share dataIART EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.62
PEG (5Y)N/A
EPS Next 2Y7.98%
EPS Next 3Y7.77%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IART Dividend Analysis

5.1 Amount

  • IART does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IART Fundamentals: All Metrics, Ratios and Statistics

INTEGRA LIFESCIENCES HOLDING

NASDAQ:IART (3/6/2026, 8:24:59 PM)

After market: 9.73 0 (0%)

9.73

-0.16 (-1.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-26
Earnings (Next)05-04
Inst Owners97.52%
Inst Owner Change1.12%
Ins Owners3%
Ins Owner Change0.16%
Market Cap758.36M
Revenue(TTM)1.64B
Net Income(TTM)-516.47M
Analysts54.12
Price Target15.81 (62.49%)
Short Float %11.35%
Short Ratio10.32
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.69%
Min EPS beat(2)1.67%
Max EPS beat(2)21.7%
EPS beat(4)3
Avg EPS beat(4)4.71%
Min EPS beat(4)-6.76%
Max EPS beat(4)21.7%
EPS beat(8)5
Avg EPS beat(8)3.77%
EPS beat(12)6
Avg EPS beat(12)3.61%
EPS beat(16)9
Avg EPS beat(16)4.3%
Revenue beat(2)0
Avg Revenue beat(2)-2.8%
Min Revenue beat(2)-4.85%
Max Revenue beat(2)-0.75%
Revenue beat(4)1
Avg Revenue beat(4)-1.01%
Min Revenue beat(4)-4.85%
Max Revenue beat(4)3.14%
Revenue beat(8)1
Avg Revenue beat(8)-1.01%
Revenue beat(12)2
Avg Revenue beat(12)-1.1%
Revenue beat(16)3
Avg Revenue beat(16)-0.92%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.84%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.08%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.41%
Valuation
Industry RankSector Rank
PE 4.36
Fwd PE 4.08
P/S 0.46
P/FCF N/A
P/OCF 15.05
P/B 0.73
P/tB N/A
EV/EBITDA 7.19
EPS(TTM)2.23
EY22.92%
EPS(NY)2.39
Fwd EY24.52%
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)0.65
OCFY6.64%
SpS20.98
BVpS13.39
TBVpS-9.06
PEG (NY)0.62
PEG (5Y)N/A
Graham Number25.92
Profitability
Industry RankSector Rank
ROA -14.34%
ROE -49.5%
ROCE 5.5%
ROIC 4.34%
ROICexc 4.74%
ROICexgc 12.06%
OM 10.58%
PM (TTM) N/A
GM 56.62%
FCFM N/A
ROA(3y)-4.24%
ROA(5y)-0.72%
ROE(3y)-15.23%
ROE(5y)-5.13%
ROIC(3y)5.05%
ROIC(5y)5.6%
ROICexc(3y)5.53%
ROICexc(5y)6.31%
ROICexgc(3y)19.84%
ROICexgc(5y)22.5%
ROCE(3y)6.39%
ROCE(5y)7.09%
ROICexgc growth 3Y-20.99%
ROICexgc growth 5Y-10.51%
ROICexc growth 3Y-13.95%
ROICexc growth 5Y-5.53%
OM growth 3Y-17.47%
OM growth 5Y-7.89%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.52%
GM growth 5Y-2.59%
F-Score4
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 1.66
Debt/FCF N/A
Debt/EBITDA 5.33
Cap/Depr 62.99%
Cap/Sales 5.85%
Interest Coverage 2.12
Cash Conversion 15.51%
Profit Quality N/A
Current Ratio 2.54
Quick Ratio 1.46
Altman-Z 1.19
F-Score4
WACC7.1%
ROIC/WACC0.61
Cap/Depr(3y)66.1%
Cap/Depr(5y)55.65%
Cap/Sales(3y)5.76%
Cap/Sales(5y)4.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.89%
EPS 3Y-12.69%
EPS 5Y-1.86%
EPS Q2Q%-14.43%
EPS Next Y7.01%
EPS Next 2Y7.98%
EPS Next 3Y7.77%
EPS Next 5YN/A
Revenue 1Y (TTM)1.53%
Revenue growth 3Y1.63%
Revenue growth 5Y3.57%
Sales Q2Q%-1.74%
Revenue Next Year2.71%
Revenue Next 2Y3.05%
Revenue Next 3Y2.86%
Revenue Next 5YN/A
EBIT growth 1Y-5.3%
EBIT growth 3Y-16.12%
EBIT growth 5Y-4.59%
EBIT Next Year25.02%
EBIT Next 3Y12.61%
EBIT Next 5YN/A
FCF growth 1Y-401.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-61.06%
OCF growth 3Y-42.46%
OCF growth 5Y-24.38%

INTEGRA LIFESCIENCES HOLDING / IART FAQ

Can you provide the ChartMill fundamental rating for INTEGRA LIFESCIENCES HOLDING?

ChartMill assigns a fundamental rating of 3 / 10 to IART.


What is the valuation status for IART stock?

ChartMill assigns a valuation rating of 7 / 10 to INTEGRA LIFESCIENCES HOLDING (IART). This can be considered as Undervalued.


What is the profitability of IART stock?

INTEGRA LIFESCIENCES HOLDING (IART) has a profitability rating of 3 / 10.


What is the financial health of INTEGRA LIFESCIENCES HOLDING (IART) stock?

The financial health rating of INTEGRA LIFESCIENCES HOLDING (IART) is 3 / 10.